ARIC Manuscript Proposal # 1854

PC Reviewed: 10/11/11 SC Reviewed:	Status: <u>A</u> Status:	Priority: <u>2</u> Priority:
1.a. Full Title : Genome-wide assoacids in plasma phospholipids: CH		•
b. Abbreviated Title (Length 2	6 characters): GWAS of odd	numbered fatty acids
2. Writing Group members: Qi Siscovik, Bruce Psaty, Joshua Bis, Ke Nettleton, Mike Tsai, Steve Rich, Ani Dariush Mozaffarian, Frank Hu, Eric Ithe fatty acid working group	nneth Rice, Barbara McKnight, Manichaikul, Myriam Fornage,	Irena King, Jennifer Donna Arnett, Jason Wu,
Additional authors TBD (this is a mul cohorts, including other cohorts from list: ARIC, CARDIA, CHS, InCHIANT Professionals' Followup Study)	the CHARGE Plasma Fatty Acid	ls Working Group, tentative
I, the first author, confirm that all the opposalQS [please confirm v	-	_
First author: Qi Sun, MD	, PhD	
Address: Harvard School of I	Public Health	
Phone:	Fax:	

ARIC author to be contacted if there are questions about the manuscript and the first author does not respond or cannot be located (this must be an ARIC investigator).

Name: Lyn Steffen

Address: University of Minnesota School of Public Health Division of Epidemiology 1300 South Second St, Suite 300

Minneapolis, MN 55454

Email: qisun@hsph.harvard.edu

Phone: 612-625-9307 Fax: 612-624-0315

E-mail: steffen@umn.edu

3. Timeline:

6-9 months: individual center analysis; meta-analysis

6 months: writing the manuscript

4. Rationale:

Odd-numbered chain fatty acids (OCFAs) are primarily produced by bacteria and other lower organisms. These fatty acids can be found in most animal tissues, although the levels are especially high in tissues of ruminant animals probably because ruminal microorganisms have particularly strong capacity of synthesizing OCFAs. Because human body cannot produce OCFAs through *de novo* synthesis, levels of these fatty acids in human tissues are determined by their intake levels and post-absorption metabolism within human body. A moderate to strong correlation was found between levels of certain OCFAs (15:0 and 17:0) and dairy fat intake in human observational studies, ³⁻⁵ suggesting that at least some of OCFAs can be used as biomarkers of dairy fat consumption. However, it is unknown whether there are other factors, related to either diet or metabolism, that determine the levels of these fatty acids in human body.

5. Main Hypothesis/Study Questions:

In this analysis, we aim to shed light on the genetic determinants for the levels of OCFAs in plasma in a genome-wide association (GWA) analysis within the CHARGE Fatty Acid Consortium.

6. Design and analysis (study design, inclusion/exclusion, outcome and other variables of interest with specific reference to the time of their collection, summary of data analysis, and any anticipated methodologic limitations or challenges if present).

1. Outcomes:

Levels of the following fatty acids in plasma phospholipids or erythrocytes:

- a) 15:0 (if available)
- b) 17:0 (if available)
- c) Sum of 15:0 and 17:0 (if both fatty acids are non-missing)
- d) 19:0 (available in the NHS and HPFS only)
- e) 21:0 (available in the NHS and HPFS only)
- f) 23:0 (available in the ARIC, NHS and HPFS only)

2. Inclusion/exclusion criteria for participants:

Inclusion: participants with European ancestry only.

Exclusion: Missing data of 15:0 AND 17:0.

3. GWA analysis

- a) Genotypes: Genotyped SNPs or imputed HapMap CEU SNPs (release r22).
- b) Chromosomes: All chromosomes excluding the sex-chromosomes
- c) Additive models using linear regression that takes into account uncertainty of imputation (i.e., dosage of imputed SNP alleles should be used). Robust variance estimators will be applied to derive standard errors and to calculate P values.
- d) Covariates: age (yr), gender, case-control status (if case-control study), study site (if applicable), population substructure (if needed, based on your judgment, please adjust principal components to correct for population stratification)
- e) Separate models for each fatty acid outcome.

4. Meta-analysis:

- a) Fixed-effects model
- b) Weighed by using the inverse of the corresponding standard errors
- c) Significance threshold: $P < 5 \times 10^{-8}$
- d) Final QC step at meta-analysis stage: effect sample size > 150.

References

- Rezanka T, Sigler K. Odd-numbered very-long-chain fatty acids from the microbial, animal and plant kingdoms. Prog Lipid Res 2009; 48(3-4): 206-38
- Wu Z, Palmquist DL. Synthesis and biohydrogenation of fatty acids by ruminal microorganisms in vitro. J Dairy Sci 1991; **74**(9): 3035-46.
- Wolk A, Furuheim M, Vessby B. Fatty acid composition of adipose tissue and serum 3. lipids are valid biological markers of dairy fat intake in men. J Nutr 2001; **131**(3): 828-33.
- 4. Wolk A, Vessby B, Ljung H, Barrefors P. Evaluation of a biological marker of dairy fat
- e

intake. Am J Clin Nutr 1998; 68 (2): 291-5.	
5. Sun Q, Ma J, Campos H, Hu FB. Plasma and erythrocy	yte biomarkers of dairy fat intake
and risk of ischemic heart disease. Am J Clin Nutr 2007; 86 (4):	: 929-37.
7.a. Will the data be used for non-CVD analysis in this No	s manuscript?X Yes
b. If Yes, is the author aware that the file ICTDER03 persons with a value RES_OTH = "CVD Research	
for DNA analysis RES_DNA = "CVD Research" v	would be used? _X Yes
No	
(This file ICTDER03 has been distributed to ARIC P	
the responses to consent updates related to stored san	nple use for research.)
8.a. Will the DNA data be used in this manuscript? No	GWAS dataX_ Yes

8.b. If yes, is the author aware that either DNA data distributed by the Coordinating Center must be used, or the file ICTDER03 must be used to exclude those with value RES_DNA = "No use/storage DNA"? XYesNo
9. The lead author of this manuscript proposal has reviewed the list of existing ARIC Study manuscript proposals and has found no overlap between this proposal and previously approved manuscript proposals either published or sti in active status. ARIC Investigators have access to the publications lists under the Study Members Area of the web site at: http://www.cscc.unc.edu/ARIC/search.php
X Yes No
10. What are the most related manuscript proposals in ARIC (authors are encouraged to contact lead authors of these proposals for comments on the new proposal or collaboration)? Other GWAS fatty acid manuscripts are similar – except that different fatty acids have been examined.
11.a. Is this manuscript proposal associated with any ARIC ancillary studies or use any ancillary study data? XYesNo
Aaron Folsom's analysis of Minnesota plasma for fatty acids.
11.b. If yes, is the proposal _X_ A. primarily the result of an ancillary study (list number* no number) Fatty acid data analyzed in Minnesota only
B. primarily based on ARIC data with ancillary data playing a mino role (usually control variables; list number(s)*
*ancillary studies are listed by number at http://www.cscc.unc.edu/aric/forms/

12a. Manuscript preparation is expected to be completed in one to three years. If a manuscript is not submitted for ARIC review at the end of the 3-years from the date of the approval, the manuscript proposal will expire.

12b. The NIH instituted a Public Access Policy in April, 2008 which ensures that the public has access to the published results of NIH funded research. It is your responsibility to upload manuscripts to PUBMED Central whenever the journal does not and be in compliance with this policy. Four files about the public access policy from http://publicaccess.nih.gov/ are posted in http://publicaccess.nih.gov/submit_process_journals.htm shows you which journals automatically upload articles to Pubmed central.